NEW YORK--(BUSINESS WIRE)--Aug. 22, 2006--INNOVIVE Pharmaceuticals, Inc., a public biopharmaceutical company headquartered in Manhattan, announced today that it has licensed the patent rights from KTB Tumorforschungs GmbH, a free-standing research institute based in Freiburg, Germany, for the worldwide development and commercialization of DOXO-EMCH, a novel doxorubicin prodrug. INNOVIVE has renamed the compound INNO-206 and plans to initiate a phase II study in a solid tumor indication shortly.
